Until now, the main findings regard the above-mentioned GNbAC1 monoclonal Ab, targeting HERV-W/MSRV Env proteins and proposed as innovative therapy for MS and type I diabetes. Here, ERVW-1 is linked to type 1 diabetes mellitus.